EVUSHELD EFFICACY AND SAFETY IN AUTOIMMUNE RHEUMATIC DISEASES TREATED BY RITUXIMAB: A PROSPECTIVE OBSERVATIONAL TRIAL
DOI:
https://doi.org/10.61841/jvcavz40Keywords:
Evusheld, COVID-19 infection, B-cell depletion therapy, autoimmune rheumatic diseaseAbstract
Background: B cell depleting therapy (rituximab) results in impaired ability to mount a humoral immune response. Evusheld, tixagevimab 150mg co-packaged with cilgavimab 150mg, is a passive vaccine against SARS-CoV-2.
Objective: Evaluate prospectively the efficacy and safety of Evusheld vaccine for preventing or mitigating SARS-COV2 infection in patients with autoimmune rheumatic diseases (AIRD) treated with rituximab.
Methods: We compared patients treated with rituximab, who agreed to receive Evusheld, to patients who refused. The primary outcome was the risk of severe COVID19 infection from omicron variant.
Results: 45 AIRD patients in the intervention group and 26 in the control group, were recruited. There was no difference between the groups with regard to sex, age, years of rituximab treatment, previous mRNA vaccination and serum immunoglobulins level. No difference in the infection rate was found between intervention group and control group (21 (49%) versus 12 (48%). Four patients had a severe infection, 3 in the control group and 1 in the intervention group. Evusheld reduced the risk for severe infection by 94% (HR 0.06, 95% CI 0.01-0.76, p-value 0.017). No adverse events were reported.
Conclusions: Evusheld decreased the risk for severe COVID19 infection in patients with AIRD treated with rituximab in a period in which Omicron BA.5, BQ1 and BQ.1.1 variants were prevalent in Israel, with a favorable safety profile.
References
Roll P, Mahmood Z, Muhammad K, Feuchtenberger M, Dörner T, Tony HP. Long-term repopulation of peripheral B-cell subsets after single and repeated rituximab infusions in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2015;33(3):347-53
Magliulo D, Wade SD, Kyttaris VC. Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: Effect of timing and immunologic parameters. Clin Immunol. 2022; 234:108897.
Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ, Ambery P, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Near KA, Padilla KW, Psachoulia K, Sharbaugh A, Streicher K, Pangalos MN, Esser MT; PROVENT Study Group. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022;386(23):2188-2200.
Ocon AJ, Mustafa SS. Real-World Experience of Tixagevimab and Cilgavimab (Evusheld) in Rheumatologic Patients on Rituximab. J Clin Rheumatol. 2023 Mar 1;29(2):109-111.
Marshall, John C., et al. "A minimal common outcome measure set for COVID-19 clinical research." The Lancet Infectious Diseases 20.8 (2020): e192-e197.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Lisa Kaly , Mark Volevich, Shiri Keret, Aniela Shoval, Itzhak Rosner, Michael Rozenbaum , Nina Boulman , Emilia Hardak , Gleb Slobodin , Doron Rimar (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
